Status:
COMPLETED
Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From AML Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)
Lead Sponsor:
West Virginia University
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18-100 years
Brief Summary
Treatment options and clinical outcomes for acute myeloid leukemia (AML) have not improved for more than 40 years. AML patients are still suffering from receiving costly, ineffective chemotherapy trea...
Detailed Description
The proposed study will be an open-label prospective investigation using fresh bone marrow and paired peripheral blood samples obtained from patients with AML starting at the time of diagnosis and inc...
Eligibility Criteria
Inclusion
- Newly diagnosed, relapsed, or refractory (post induction therapy) AML patients age \> 18
- For relapsed AML patients, previous treatment regimens received do not limit their eligibility to this study
- Patients enrolled will have no limitation as to the type of treatment they receive for their disease.
- Patient is able to give consent
Exclusion
- AML-M3 patients
- AML patients age \< 18
- AML patients in clinical remission
- AML patients who will not be able to receive diagnostic blood and marrow work up for any reason
- Patients who received allogeneic stem cell transplantation or autologous stem cell transplantation
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT01203033
Start Date
September 1 2010
End Date
October 1 2012
Last Update
February 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MBRCC, West Virginia University
Morgantown, West Virginia, United States, 26506